Novo Nordisk said an older version of its weight-loss drug semaglutide failed to meet its main goal in late-stage trials ...

The weight-loss drug eloralintide shows up to 20% body weight reduction in trial, offering hope for obesity treatment beyond ...

Pedersen COPENHAGEN (Reuters) -Novo Nordisk's closely-watched Alzheimer's trials of an older oral version of its semaglutide ...

Novo Nordisk said an older version of its weight-loss drug semaglutide failed to meet its main goal in late-stage trials ...

GLP-1 drugs like Wegovy and Zepbound have been racking up sales and new indications, as researchers learn more about how the ...

Traditional weight management methods, like restrictive diets and time-consuming exercise regimens, can feel impossible to ...

Eli Lilly, the maker of hugely popular weight loss drugs, has reached $1 trillion in value, becoming the first publicly ...

Trial participants who used eloralintide, a new weight loss medication that, instead of focusing on the hormone GLP-1, ...

Lilly becomes the first pharmaceutical company to hit that threshold, joining a select club of mostly tech companies.

Eli Lilly said on Friday it plans to roll out an employer-focused obesity care model early next year, aiming to expand access ...

Novo Nordisk announced on Monday that it is lowering costs for weight loss and diabetes drugs, weeks after it struck a deal ...

Chrissy had a medical reason. The post Chrissy Teigen’s Tragic Reason for Using Weight-Loss Drug appeared first on Reality ...